A recent study, led by UKDTN’s Director – Professor Catherine Mummery – evaluated ImmunoBrain’s IBC-Ab002, a monoclonal antibody designed to modulate immune responses associated with Alzheimer’s Disease and support the brain’s repair processes.
Results from the phase 1b trial, shared at ADPD 2026 in Copenhagen, involved 40 participants with early Alzheimer’s Disease across the UK, the Netherlands and Israel.
The ImmunoBrain study was among first trials led by UKDTN, enabling coordinated delivery across several UK sites and demonstrating the value of a national, harmonised trial infrastructure. The drug was found to be safe and well tolerated, with early biomarker signals showing promise to impact on the course of the disease.
For more information on this trial, visit: https://immunobrain.com/lead-program/ibc-ab002-antibody/
By UKDTNAdmin